Integrated multi-biomarker panel of CXCL13, HS-CRP, and WBC counts predicts outcomes in stroke neurosyphilis patients treated with HBO and TUS-NMES.

Front Neurol · 2025 · PMC11894733 · PMID 40070668

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantp < 0.001actually significant

Comparison of CXCL13, WBC, Hs-CRP in cerebrospinal fluid of stroke patients with neurosyphilis before and after treatment The CXCL13 level before treatment was (132.91 ± 12.31) μg/mL, which decreased to (98.39 ± 8.37) μg/mL after 4 weeks of treatment, showing a highly significant difference between the two ( t = 29.15, p < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.